All Trials

A Phase I/Ib Trial of ProAgio, an Anti-avb3 Integrin Cytotoxin, in Combination With 5-fluorouracil , Irinotecan and Bevacizumab for Advanced/Metastatic Colorectal Cancer (ProAgio in CRC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated advanced/metastatic colorectal adenocarcinoma (ECOG 0–1), measurable disease, and adequate organ function receive ProAgio—an investigational pegylated peptide that targets integrin αvβ3 on cancer-associated fibroblasts and endothelial cells to induce apoptosis and remodel stroma—combined with FOLFIRI (irinotecan/infusional 5-FU) plus bevacizumab. Prior FOLFOX for adjuvant disease >1 year is allowed in expansion, while prior FOLFIRI or 5-FU–based therapy for metastatic disease is excluded.

ClinicalTrials.gov ID: NCT06867822

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory gastrointestinal cancers (gastric adenocarcinoma [CDH17+], colorectal adenocarcinoma, or well-differentiated mid/hindgut NETs) receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of CHM-2101, an autologous third-generation CAR T therapy targeting cadherin-17. Single-arm dose escalation/expansion; bridging chemo allowed between leukapheresis and lymphodepletion.

ClinicalTrials.gov ID: NCT06055439

Phase I Study of Intraventricular Infusion of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) in Subjects With Recurrent or Refractory Glioblastoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent or refractory glioblastoma (supratentorial or infratentorial) post-surgery/biopsy and ≥40.05 Gy RT with concurrent temozolomide, KPS >60%, and no prior anti-angiogenic or CAR T therapy receive up to three weekly intraventricular infusions of autologous CAR T cells targeting B7-H3 (CD276). Therapy is delivered via the ventricular system to enhance CNS distribution; study focuses on safety, CRS/neurotoxicity, and preliminary antitumor activity.

ClinicalTrials.gov ID: NCT05366179

Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent/refractory EGFR-overexpressing high-grade gliomas (GBM, anaplastic astrocytoma/oligoastrocytoma) after Stupp protocol receive superselective intra-arterial cetuximab following mannitol BBB disruption plus hypofractionated re-irradiation. Cetuximab is an anti-EGFR IgG1 monoclonal antibody that blocks EGFR signaling and mediates ADCC; eligibility requires measurable disease and KPS ≥60%.

ClinicalTrials.gov ID: NCT02800486

REMASTer: REcurrent Brain Metastases After SRS Trial

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with a single brain metastasis showing radiographic progression after prior SRS are randomized via an intraoperative pathology–guided algorithm to LITT (NeuroBlate MRI-guided thermal ablation) with or without hypofractionated re-irradiation if recurrent tumor, or to LITT plus steroids versus steroids alone if radiation necrosis. Designed to test local control after ablation in true recurrence and time to steroid independence in radiation necrosis.

ClinicalTrials.gov ID: NCT05124912

Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With GD2-expressing Brain Tumors (GAIL-B)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Pediatric and young adult patients (12 months–22 years) with GD2-expressing CNS tumors—including diffuse midline glioma/high-grade glioma and select other high-grade brain tumors—receive lymphodepletion (cyclophosphamide/fludarabine) followed by autologous GD2-directed CAR T cells engineered with a constitutively active IL‑7 receptor (C7R) to enhance persistence. Cohort 1 gets initial IV CAR T then intracerebroventricular dosing via Ommaya/VP shunt; Cohort 2 (recurrent/progressive pontine HGG or H3K27-altered DMG) receives IV only.

ClinicalTrials.gov ID: NCT04099797

SJ901: Phase 1/2 Evaluation of Single Agent Mirdametinib (PD-0325901), a Brain-Penetrant MEK1/2 Inhibitor, for the Treatment of Children, Adolescents, and Young Adults With Low-Grade Glioma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling patients aged 2 to <25 years with centrally confirmed MAPK-activated WHO grade I–II pediatric low-grade glioma (including eligible glioneuronal/neuroepithelial tumors), across newly diagnosed and recurrent/progressive settings, with measurable/evaluable disease; excludes BRAF V600, NTRK/ALK/ROS1 fusions, IDH1/2, and significant ocular/cardiac/hepatic/pulmonary comorbidity. Investigational therapy is oral single-agent mirdametinib, a selective brain-penetrant MEK1/2 inhibitor targeting MAPK/ERK signaling, given BID in 28-day cycles; cohorts include MEK inhibitor–naïve and previously MEK-exposed patients.

ClinicalTrials.gov ID: NCT04923126

A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with recurrent high-grade glioma (IDH-mutant grade 3/4 astrocytoma or IDH-wildtype glioblastoma) after standard therapy, with tumors suitable for convection-enhanced delivery and meeting RANO progression and performance criteria. Single intratumoral infusion of 186Rhenium nanoliposomes via CED, a beta-emitting radiotherapeutic encapsulated in nanoliposomes to deliver localized high-dose radiation with imageable distribution (SPECT); excludes multifocal/leptomeningeal disease, infratentorial tumors, recent bevacizumab or radiation, and lesions risking ventricular/subarachnoid leak.

ClinicalTrials.gov ID: NCT01906385

Phase I/II Study of Lutathera in Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Demonstrate Uptake on DOTATATE PET

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling children to young adults (ages 4–39) with recurrent/progressive high-grade primary CNS tumors or meningiomas that are SSTR-positive on DOTATATE PET (Krenning ≥2). Participants receive 177Lu-DOTATATE (Lutathera), a somatostatin receptor 2–targeted peptide receptor radionuclide therapy delivering beta-emitting 177Lu, IV every 8 weeks for up to 4 cycles.

ClinicalTrials.gov ID: NCT05278208

Phase I/II Trial of Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed, EGFR-overexpressing glioblastoma receive super-selective intra-arterial cetuximab after mannitol blood–brain barrier disruption at set postoperative intervals, in addition to standard Stupp chemoradiation. Cetuximab is an anti-EGFR IgG1 monoclonal antibody that blocks EGFR signaling and may mediate ADCC.

ClinicalTrials.gov ID: NCT02861898